Cost-Effectiveness Analysis of the mRNA-1345 RSV Vaccine for Adults in the United States: Clinical and Economic Value
Notice bibliographique
Résumé
ABSTRACT Background The clinical and economic burden of respiratory syncytial virus (RSV) is significant; millions of patients seek medical care due to RSV infections each year. Recently approved vaccines offer an important opportunity to reduce this burden in populations that are at high risk due to certain medical conditions or older age. This study evaluates the public health impact and cost-effectiveness of vaccination with mRNA-1345 against RSV in adults. Methods A static decision-analytic model was developed to estimate the public health impact and cost-effectiveness of vaccinating high-risk adults aged 18-59 years and all adults aged ≥ 60 years in the 5-year period following vaccination against RSV with a single dose of mRNA-1345 in the United States (US). RSV vaccination rates in the analysis were assumed to be equal to 2019-2020 influenza season vaccination rates. Vaccine effectiveness against RSV-related acute respiratory disease and RSV-associated lower respiratory tract infection over time was modeled using nonlinear waning curves that reflect clinical trial data. Results According to the model, vaccinating the high-risk adult US population aged 18-59 years and all US adults aged ≥ 60 years with mRNA-1345 would avert over 280,000 hospitalizations, 19,000 deaths, and result in about 244,000 quality-adjusted life-years gained compared with an unvaccinated population over a 5-year period. Vaccination costs approximately $23.2 billion and reduces direct and indirect costs by $10.8 billion and $13.3 billion, respectively, resulting in net savings of more than $810 million from a societal perspective, making vaccination with mRNA-1345 in this population cost saving. Conclusions Vaccination with mRNA-1345 is a cost-saving strategy for the prevention of RSV in high-risk and older US adults and has the potential for substantial public health impact. KEY SUMMARY POINTS Why carry out this study? (1-2 bullets) The clinical and economic burden of respiratory syncytial virus (RSV) in high-risk and older adults is significant The mRNA-1345 RSV vaccine has been approved in adults aged ≥ 60 years in 2024 and high-risk adults 18-59 years old in 2025, but the potential clinical benefit and cost-effectiveness of RSV vaccination has not been established. What did the study ask?/What was the hypothesis of the study? (1 bullet) The study objective was to examine the public health impact and cost-effectiveness of RSV vaccination with mRNA-1345 compared with no vaccination in high-risk adults aged 18-59 years and all adults aged ≥ 60 years in the United States (US) in the 5-year period following vaccination. What were the study outcomes/conclusions? (1 bullet point) Vaccination with mRNA-1345 results in 280,000 fewer hospitalizations, over 19,000 fewer deaths, and over $810 million in economic savings from a societal perspective compared with not vaccinating against RSV over a 5-year period. What has been learned from the study? (1-2 bullets) These analyses suggest the mRNA-1345 vaccine is a cost-saving strategy for the prevention of RSV in US adults across age groups and has the potential for substantial public health impact. Our findings may inform clinical and policy decision-making regarding the value of RSV vaccination in adults and support efforts to expand access among younger high-risk populations. PLAIN LANGUAGE SUMMARY Respiratory syncytial virus (RSV) is a common virus that causes lung infections. It can be especially dangerous for older adults and people with health conditions like asthma, heart disease, or diabetes. Each year, RSV causes many hospital stays and even deaths in the United States. A new vaccine called mRNA-1345 was recently approved to protect adults aged 60 and older, and high-risk adults aged 18-59. This study looked at whether giving the vaccine to these groups would help prevent RSV infections and save money. Researchers used a mathematical model to compare what might happen over 5 years with and without the vaccine. They found that the vaccine could prevent over 280,000 hospital stays and more than 19,000 deaths. Even though the vaccine costs money, it would save more than $800 million by reducing medical bills and helping people stay healthy and working. RSV can place a heavy burden on individuals and the healthcare system. This study shows that the mRNA-1345 vaccine could protect the most vulnerable adults while also being a valuable investment for society.
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
Comment cette classification a été obtenuedéplier
Prédiction machine sur la base complète
Imitation des enseignantsNi prévalence calibrée, ni vérité terrain. Validation humaine à venir. Le volet Gemma est une étiquette directe du modèle pour chaque travail de la base, lue sur la notice réduite au titre. Le volet Codex est un classifieur appris des 10 348 étiquettes directes de Codex et calibré sur les taux pondérés de l'échantillon; les champs sans appui suffisant ne portent aucun appel Codex. Le mode candidate est l'union des deux volets; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont pas des étiquettes humaines.
Scores du classifieur distillé par catégorie (deux têtes)
| Catégorie | Codex | Gemma |
|---|---|---|
| Métarecherche | 0,008 | 0,022 |
| Méta-épidémiologie (sens strict) | 0,002 | 0,001 |
| Méta-épidémiologie (sens large) | 0,002 | 0,004 |
| Bibliométrie | 0,002 | 0,002 |
| Études des sciences et des technologies | 0,000 | 0,001 |
| Communication savante | 0,002 | 0,002 |
| Science ouverte | 0,001 | 0,001 |
| Intégrité de la recherche | 0,001 | 0,001 |
| Charge utile insuffisante (le modèle a refusé de juger) | 0,004 | 0,000 |
Scores machine (provisoires)
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découleClassification
machine, non validéePrédiction automatique; un appel candidat d’une seule source (Gemma direct ou Codex distillé), pas un consensus.
Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».